CDEK
← All drugs Report issue

allisartan isoproxil

Small moleculeexperimental

Clinical trial activity

8 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
5

Earliest trial started Nov 1, 2016 (NCT02893358)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • allisartan isoproxil
  • allisartan isoproxil
  • als-3 compound

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07174830Phase 4Sep 6, 2025Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen University
NCT06500689Phase 3Dec 30, 2021Shenzhen Salubris Pharmaceuticals Co., Ltd.
NCT04978649Phase 4Sep 1, 2021Shantou University
NCT06465264Phase 3Apr 29, 2021Shenzhen Salubris Pharmaceuticals Co., Ltd.
NCT05033535Phase 2Jul 1, 2020Shenzhen University
NCT04111419Phase 4Nov 1, 2019Jiao Tong University
NCT03264352Phase 4Feb 28, 2018Shantou University
NCT02893358Phase 4Nov 1, 2016Jiao Tong University, West China Hospital
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shenzhen Salubris Pharmaceuticals Co., Ltd.For profit3322021
Jiao Tong UniversityAcademic/Hospital2112016
Shantou UniversityAcademic/Hospital2212018
Shenzhen UniversityAcademic/Hospital2122020
West China HospitalAcademic/Hospital1112016
5 organizations
Page 1 / 1